Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD Isabella Ciccone, MPH

In a newly published study, researchers developed expert-driven, evidence-based, up-to-date consensus recommendations for managing neuromyelitis optica spectrum disorder in Saudi Arabia.

Treating Obstructive Sleep Apnea: Beyond CPAP and Toward Hypoglossal Nerve Stimulation Vaishal Shah, MD, MPH, FAASM, FAAP

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Building the Next Era of ALS Clinical Research and Trials Marco Meglio

Ryan Donaghy, MD, an assistant professor of neurology at Northwestern Medicine, discussed the evolving landscape of ALS clinical trials, including advances in biomarkers, genetics, and modern trial design.

NeurologyLive® Friday 5 — November 14, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 14, 2025.

Todays Updates

Multi-Arm Phase 2 Trial Fails to Show Efficacy for Cognitive Programs in Treating Long COVID Marco Meglio

A recent trial reveals that online cognitive training and other interventions are ineffective for treating long COVID cognitive symptoms, highlighting treatment challenges.

Todays Updates

Multi-Arm Phase 2 Trial Fails to Show Efficacy for Cognitive Programs in Treating Long COVID Marco Meglio

A recent trial reveals that online cognitive training and other interventions are ineffective for treating long COVID cognitive symptoms, highlighting treatment challenges.

Latest News

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

In a newly published study, researchers developed expert-driven, evidence-based, up-to-date consensus recommendations for managing neuromyelitis optica spectrum disorder in Saudi Arabia.

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Ryan Donaghy, MD, an assistant professor of neurology at Northwestern Medicine, discussed the evolving landscape of ALS clinical trials, including advances in biomarkers, genetics, and modern trial design.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 14, 2025.

News All Time

Study Forecasts Uptick in ALS Prevalence in Coming Decades Isabella Ciccone, MPH

Results of a new study funded by the ALS Association showed that the global prevalence of patients living with amyotrophic lateral sclerosis may increase by 25% by 2040.

Targeting Myasthenia Gravis at the Source: Promising Progress of CAR-T Agent KYV-101 Marco Meglio

Naji Gehchan, MD, MSc, chief medical and development officer Kyverna, discussed how KYV-101 may redefine generalized myasthenia gravis care through deep B-cell depletion and durable, drug-free remission.

Exploring the Growth and Challenges of Genetic Counseling Louie Pasculli, Carrie Haverty, MS, CGC

Carrie Haverty, MS, CGC, NSGC president-elect, discusses the evolving role of genetic counselors, emphasizing personalized care, gene therapy advancements, and the need for multidisciplinary integration in health care.

NeuroVoices: Tanya Simuni, MD, FAAN, on Emerging Directions in Disease-Modifying Therapy Trials for Parkinson Disease Tanya Simuni, MD, FAAN, Isabella Ciccone, MPH

At MDS 2025, the professor of neurology at Northwestern University Feinberg School of Medicine discussed the evolving landscape of disease-modifying clinical trials in Parkinson disease.

Mild cognitive impairment, dementia risk up with increasing biological severity of Alzheimer's disease

For individuals who are currently cognitively unimpaired, the lifetime and 10-year absolute risk of mild cognitive impairment (MCI) and dementia increases with increasing amyloid positron emission tomography (PET) centiloid ...

Parents of neurodivergent kids need support. But those who need it most often wait longer

Parenting any young child is full of highs and lows. In addition to these, parents and caregivers of children with neurodevelopmental conditions such as autism and attention-deficit hyperactivity disorder (ADHD) are more ...

Study shows over 90% of older adults with dementia undergo burdensome interventions in their final year

A new study by researchers from Duke-NUS Medical School has revealed that almost all community-dwelling older adults with advanced dementia in Singapore experience at least one potentially burdensome intervention in their ...

Gene 'switch' reverses Alzheimer's risk in experimental model

University of Kentucky researchers have developed a new experimental model that could point the way toward more effective Alzheimer's disease treatments by targeting one of the brain's most important genes for risk and resilience.

What polymers can teach us about curing Alzheimer's disease

Researchers from Tokyo Metropolitan University have applied ideas from polymer physics to illuminate the mechanism behind a key pathology in Alzheimer's disease, the formation of fibrils of tau proteins. They showed that ...

Next-generation microbiome medicine may transform Parkinson's treatment

The age-old advice to "trust your gut" could soon take on new meaning for people diagnosed with Parkinson's disease, thanks to a creative feat of bioengineering by researchers in the University of Georgia's College of Veterinary ...

How people identify scents and perceive their pleasantness

In a new JNeurosci paper, Masako Okamoto and colleagues, from the University of Tokyo, explored the brain activity involved in smelling odors.

Brain stimulation found to improve vision recovery after stroke

Scientists at EPFL have developed an innovative, non-invasive brain stimulation therapy to significantly improve visual function in stroke patients who have suffered vision loss following a stroke. The approach could offer ...

How to keep dementia from robbing your loved ones of their sense of personhood—tips for caregivers

Every three seconds, someone in the world develops dementia. There are over 6 million people living with dementia in the U.S. and 57 million globally.

Poor sleep may nudge the brain toward dementia, researchers find

Staring at the ceiling while the clock blinks 3am doesn't only sap energy for the next day. A large, long-running U.S. study of older adults has now linked chronic insomnia to changes inside the brain that set the stage for ...

Exercise-induced vesicles boost neuron growth when transplanted into sedentary mice

Researchers at the University of Illinois Urbana-Champaign report that extracellular vesicles released into the bloodstream during aerobic exercise can, on their own, drive a robust increase in adult hippocampal neurogenesis ...

How brain fluid flow predicts survival in glioblastoma

Glioblastoma—the most aggressive form of brain cancer—remains one of medicine's biggest challenges. Despite surgery, radiotherapy, and chemotherapy, most patients survive only about a year after diagnosis.

Recommended News For You

Understudied mental health challenges among caregivers of cancer patients: A call for targeted support

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

Children living near oil and gas wells face higher risk of rare leukemia, studies show

Study reveals that older women frequently receive an incorrect breast cancer diagnosis.

New CAR T-Cell Therapy Approved for Leukemia

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

Modified personalized cancer vaccine generates powerful immune response

Recommended Articles For You

Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies 

A New Hope: How Procarbazine is Revolutionizing Cancer Treatment 

Exploring the Benefits of Teclistamab for Treating Advanced Cancer 

Radiation Oncology Advances: Guidelines, Trials, Digital Tools & Education 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

2.

Life quality after childhood cancer is quantifiable thanks to outcome indicators.

3.

For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.

4.

Can certain food cravings predict a cancer diagnosis up to three months before other symptoms appear?

5.

To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.

1.

A Breakthrough in Multiple Myeloma: Darzalex Delays Disease Progression by 51%

2.

Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025

3.

Amivantamab Plus Chemotherapy Outperforms Standard Care in Post-Osimertinib NSCLC

4.

How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?

5.

Navigating the Complexity of Peritoneal Carcinomatosis: A Guide for Patients and Caregivers

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

2.

Updates on Standard V/S High Risk Myeloma Treatment

3.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective

4.

A New Era in Managing Cancer-Associated Thrombosis

5.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot